List of Excipients in Branded Drug EVZIO(R) NALOXONE HCL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	EVZIO(R) NALOXONE HCL	evzio(r) naloxone hcl	51662-1495	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	EVZIO(R) NALOXONE HCL	evzio(r) naloxone hcl	51662-1495	SODIUM CHLORIDE
HF Acquisition Co LLC DBA HealthFirst	EVZIO(R) NALOXONE HCL	evzio(r) naloxone hcl	51662-1495	WATER

EVZIO Naloxone HCl Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

EVZIO is a naloxone hydrochloride auto-injector whose commercial value came primarily from its delivery system, human-factors design, and emergency-use positioning rather than from a differentiated excipient platform. The formulation is deliberately simple: naloxone hydrochloride, sodium chloride, hydrochloric acid for pH adjustment, and water for injection. That composition limits formulation complexity but also narrows the opportunity to create meaningful composition-of-matter exclusivity.

The strongest commercial opportunities are reformulated naloxone products that improve portability, dose flexibility, storage, usability, procurement economics, or distribution. The main competitive threats are OTC naloxone nasal sprays, low-cost generic injectable products, and device-related manufacturing costs.

What is EVZIO naloxone hydrochloride?

EVZIO is a prescription naloxone hydrochloride injection delivered through a single-use auto-injector. Kaleo developed the product for rapid administration by non-health-care professionals during suspected opioid overdose. The device provides voice instructions and automated injection, reducing the number of manual steps compared with a vial-and-syringe presentation.

EVZIO was approved in 2014 at a 0.4 mg dose and later received approval for a 2 mg dose. The product is administered intramuscularly or subcutaneously. Its principal active ingredient, naloxone hydrochloride, is an opioid antagonist that reverses opioid-induced respiratory and central nervous system depression.

Attribute	EVZIO profile
Active ingredient	Naloxone hydrochloride
Delivery form	Single-use auto-injector
Initial FDA approval	2014
Approved strengths	0.4 mg and 2 mg presentations
Route	Intramuscular or subcutaneous injection
Formulation type	Sterile aqueous solution
Preservative strategy	Preservative-free presentation
Primary value proposition	Automated emergency administration
Main competitors	Naloxone nasal sprays, vials, prefilled syringes, generic injectables

The FDA-approved labeling instructs users to seek emergency medical assistance after administration because naloxone may have a shorter duration of action than some opioids and repeat dosing may be required.[1]

What excipients are used in EVZIO?

EVZIO uses a minimalist excipient system. The inactive ingredients identified in the FDA prescribing information are sodium chloride, hydrochloric acid, and water for injection.[1]

Component	Function
Naloxone hydrochloride	Active pharmaceutical ingredient
Sodium chloride	Tonicity adjustment
Hydrochloric acid	pH adjustment
Water for injection	Vehicle

The absence of antimicrobial preservatives is commercially relevant. EVZIO is a single-dose sterile product, so multidose-container preservation is unnecessary. A preservative-free product also avoids potential tolerability, compatibility, and regulatory issues associated with benzalkonium chloride, chlorobutanol, phenol, or related antimicrobial excipients.

The formulation strategy is consistent with the requirements of an emergency injectable:

• Low excipient burden
• Limited risk of excipient-related adverse reactions
• Straightforward compendial testing
• Compatibility with sterile filling
• Reduced risk of particulate formation
• Suitability for a compact single-dose cartridge or syringe

The formulation is adjusted to an acidic pH range suitable for naloxone hydrochloride stability. The FDA label identifies sodium chloride and hydrochloric acid but does not establish a differentiated excipient platform comparable to a proprietary depot system, sustained-release system, or absorption-enhancing technology.[1]

How strong is the EVZIO excipient patent estate?

EVZIO's principal defensibility is associated with the auto-injector, electronic instructions, dose delivery architecture, and methods of use. The basic aqueous naloxone formulation has limited apparent differentiation because it relies on conventional injectable excipients.

A commercial entrant would therefore face several separate IP questions:

1. Whether the proposed formulation uses the same concentration, pH range, and excipient combination.
2. Whether the product copies protected cartridge, needle, actuator, or sensor architecture.
3. Whether the device uses similar voice-prompt or user-interface functionality.
4. Whether the product claims overlap with emergency overdose treatment methods.
5. Whether any relevant patents remain enforceable in the target jurisdiction.

The excipient composition itself is unlikely to create a strong barrier unless a follow-on product demonstrates a specific technical advantage, such as improved naloxone stability, reduced adsorption to container surfaces, protection from oxidation, or compatibility with a novel delivery system.

Formulation patent opportunities

A differentiated formulation patent would need more than the use of sodium chloride, hydrochloric acid, and water for injection. Stronger claim strategies could include:

• A defined naloxone concentration and pH window that improves shelf life.
• A formulation that reduces degradation under elevated-temperature storage.
• A low-volume, high-concentration formulation for compact devices.
• A formulation compatible with a specific polymer cartridge or elastomer stopper.
• A formulation that reduces adsorption or extractables and leachables.
• A preservative-free formulation designed for repeated emergency dosing.
• A formulation optimized for autoinjector needle force and injection time.
• A ready-to-use presentation with improved stability after temperature excursions.

These claims would require comparative stability and device-performance data. A simple substitution of one conventional tonicity agent for another would face a higher obviousness risk.

When did EVZIO lose commercial exclusivity?

EVZIO's commercial exclusivity weakened as competing naloxone products expanded, particularly nasal sprays and generic injectable presentations. The product's market position also changed after FDA approval of OTC Narcan nasal spray in 2023.[2]

The relevant exclusivity layers are different:

Exclusivity layer	EVZIO relevance
New chemical entity exclusivity	Not available for naloxone, an established active ingredient
New drug application exclusivity	Limited relative to the product's device and formulation scope
Orphan exclusivity	Not applicable to ordinary opioid-overdose reversal use
Patent exclusivity	Primarily dependent on device, delivery, and use claims
Regulatory exclusivity from a novel device	Does not operate as broad market exclusivity
Brand advantage	Based on recognition, packaging, and emergency-use design

A generic or follow-on company may avoid brand patents by using a different device architecture or a conventional syringe presentation. The result is that EVZIO's practical protection is narrower than the protection of a new molecular entity.

What is the FDA regulatory status of EVZIO?

EVZIO was approved under a new drug application as a prescription naloxone auto-injector. Its regulatory value was tied to usability and rapid administration rather than a new active ingredient.

Naloxone has since moved across multiple regulatory channels:

• Prescription injectable products remain available for hospitals, emergency medical services, and institutional use.
• Naloxone nasal spray has expanded access for layperson administration.
• FDA approved Narcan naloxone hydrochloride nasal spray for nonprescription use in 2023.[2]
• FDA also approved RiVive, another OTC naloxone nasal spray, in 2023.[3]

The OTC transition changes the commercial benchmark. A new EVZIO-like product would need to justify the added cost and device complexity against nasal products that require no needle, no assembly, and no injection training.

What commercial opportunities exist for EVZIO-like excipient strategies?

1. Low-cost generic auto-injectors

A lower-cost auto-injector could target public-sector procurement, Medicaid programs, emergency departments, correctional facilities, schools, and first-responder organizations. The key barriers are:

• Device tooling and assembly cost
• Sterile drug-device integration
• Human-factors validation
• Reliability after storage and transport
• Cartridge and stopper compatibility
• Manufacturing yield
• Insurance reimbursement

A generic auto-injector must compete against inexpensive vials and increasingly accessible nasal sprays. The product requires a clear operational advantage, such as automatic voice guidance, rugged packaging, or use by personnel wearing gloves.

2. Institutional emergency kits

Hospitals and emergency services may prefer injectable naloxone for controlled clinical settings. Commercial opportunities include:

• Unit-dose prefilled syringes
• Tamper-evident overdose kits
• Multi-strength emergency kits
• Cart-ready packaging for emergency departments
• Ambulance and first-responder configurations
• Pediatric and adult dose differentiation
• Temperature-monitoring labels

The excipient strategy should remain simple and compatible with existing sterile manufacturing. The commercial differentiation would come from packaging, dosing, and workflow integration rather than from adding complex excipients.

3. Higher-concentration naloxone formulations

Higher-concentration solutions could reduce injection volume and permit smaller cartridges or more compact devices. This opportunity must be balanced against:

• Local tissue tolerability
• Accurate delivery at low volumes
• Device dose precision
• Stability at higher drug concentration
• Risk of dosing errors
• Need for repeat administration

A compact formulation may support a smaller auto-injector and reduce shipping costs. The strongest patent position would combine concentration, pH, container system, and device performance in one integrated claim strategy.

4. Heat-stable and distribution-ready products

Naloxone products are distributed through public-health channels that may expose them to temperature excursions. A formulation with improved stability under heat, freezing, or repeated temperature cycling could create value in:

• Community distribution programs
• Rural emergency response
• Outdoor and occupational settings
• Correctional facilities
• International markets
• Disaster-response stockpiles

A heat-stability claim would require robust accelerated and real-time stability data. The product could also use improved secondary packaging, thermal indicators, or insulated kits without changing the formulation.

5. Global-market presentations

The United States has a strong OTC nasal-spray market, but injectable naloxone remains relevant in many countries and institutional settings. Geographic opportunities may exist where:

• Nasal products have limited distribution
• Injectable supply is inconsistent
• Health systems use ampoules or vials
• Emergency responders require a compact presentation
• Local regulators favor established injectable pathways

A multinational strategy would need to address country-specific device registration, local manufacturing, language requirements, pharmacopoeial standards, and procurement rules.

What formulation and manufacturing barriers affect market entry?

The active ingredient is commercially available from multiple sources, so API access alone is unlikely to create a durable barrier. The harder problems are sterile manufacturing and device integration.

Sterile manufacturing risks

A sponsor must control:

• Bioburden and endotoxin
• Sterility assurance
• Fill-volume accuracy
• Container closure integrity
• Particulate levels
• Subvisible particles
• Extractables and leachables
• Naloxone assay and degradation products
• Device dose delivery after aging

Small-volume injectable products can have a narrow margin for fill-volume error. The finished device must deliver the labeled dose consistently across temperature and orientation conditions.

Device integration risks

For an auto-injector, the formulation cannot be evaluated separately from the device. Viscosity, surface tension, stopper friction, needle gauge, spring force, injection time, and residual volume all affect performance.

A formulation that works in a conventional syringe may not work in an autoinjector cartridge. Conversely, a formulation optimized for a cartridge may require different container materials or closure components. This creates a possible combination-product patent strategy, but it also increases development cost.

Which companies challenge EVZIO's commercial position?

The main competitive groups are:

Competitor category	Examples	Competitive advantage
OTC nasal spray	Narcan, RiVive	Needle-free use and broad consumer access
Generic injectable naloxone	Multiple manufacturers	Lower unit cost and institutional familiarity
Branded injectable products	Various hospital suppliers	Established procurement and supply chains
Auto-injector follow-ons	Potential generic or 505(b)(2) entrants	Simplified administration
Public-health programs	Government-purchased products	Large-volume procurement and distribution

Emergent BioSolutions commercialized Narcan nasal spray, which became the leading reference point for community naloxone access after OTC approval.[2] Harm Reduction Therapeutics developed RiVive as a nonprofit-oriented OTC product and received FDA approval in 2023.[3]

The competitive distinction is now less about whether naloxone can reverse overdose and more about access, price, training burden, storage, and delivery setting.

Are Paragraph IV challenges relevant to EVZIO?

Paragraph IV litigation is relevant where an abbreviated new drug application applicant certifies that listed patents are invalid, unenforceable, or not infringed. For a naloxone auto-injector, the scope of any challenge would depend on the Orange Book-listed patents for the reference product and the applicant's device and formulation design.

A conventional naloxone injection may avoid auto-injector claims entirely. A competing auto-injector is more likely to raise infringement questions involving:

• Automatic needle insertion
• Dose delivery mechanisms
• Voice instructions
• Cartridge structure
• Safety interlocks
• Device activation
• Packaging and user-interface methods

The business risk is highest when the applicant copies the reference device architecture. A design-around strategy can reduce patent exposure but may increase engineering and human-factors costs.

What is the Orange Book status of EVZIO?

The Orange Book remains the controlling FDA source for listed patents, exclusivity, dosage-form information, and reference-product status. EVZIO's relevant regulatory identity is its naloxone hydrochloride injection in an auto-injector presentation. Orange Book analysis should distinguish the drug product from patents covering the associated delivery device.

Because naloxone itself is an established active ingredient, the principal commercial questions are:

• Whether an EVZIO patent remains listed and unexpired.
• Whether the patent claims cover the drug, device, or method of use.
• Whether a generic applicant can certify non-infringement.
• Whether the applicant can use a different device and pursue approval without copying protected claims.
• Whether the reference product has current commercial availability sufficient for an ANDA strategy.

A follow-on company may pursue a 505(b)(2) application if it relies on the FDA's findings for naloxone but introduces a materially different device, formulation, or route. A conventional injectable product may instead use an ANDA pathway if it meets applicable sameness requirements.

How does EVZIO compare with Narcan nasal spray?

Factor	EVZIO	Narcan nasal spray
Route	Intramuscular or subcutaneous injection	Intranasal
Needle required	Yes	No
User training	Higher	Lower
OTC availability	Prescription product history	FDA-approved OTC
Device complexity	High	Moderate
Sterile injectable manufacturing	Required	Not required in the same manner
Layperson acceptance	Lower	Higher
Institutional utility	Strong	Increasing
Excipient differentiation	Limited	Nasal formulation and device dependent
Main commercial advantage	Automated injection	Simplicity and accessibility

EVZIO has a stronger fit in settings where a controlled injectable dose is preferred and trained personnel are present. Narcan has a stronger fit in community distribution and unsupervised emergency response.

What revenue exposure and launch scenarios exist?

The most attractive launch scenarios are not broad replacement of OTC nasal sprays. They are targeted segments where injection or automated delivery has a practical advantage.

Scenario 1: Institutional low-cost auto-injector

This product targets hospitals, emergency medical services, prisons, schools, and government stockpiles. Price competitiveness and reliable supply are the primary requirements.

Scenario 2: Premium ruggedized emergency device

A differentiated product could target police, industrial employers, military users, and outdoor settings. Features could include glove-compatible activation, broad temperature tolerance, loud instructions, and tamper-resistant packaging.

Scenario 3: Prefilled syringe rather than auto-injector

A prefilled syringe would reduce device complexity and cost. It would compete directly with vials and syringes but could improve dose accuracy, readiness, and inventory control.

Scenario 4: 505(b)(2) compact formulation

A higher-concentration or lower-volume presentation could support a smaller device and create formulation-device patent claims. The regulatory path may be more complex than a conventional generic but could offer greater product differentiation.

Key Takeaways

• EVZIO uses a simple preservative-free injectable formulation containing naloxone hydrochloride, sodium chloride, hydrochloric acid, and water for injection.
• The excipient composition is unlikely to provide broad standalone exclusivity.
• The strongest IP opportunities combine formulation parameters with cartridge, closure, and auto-injector performance.
• EVZIO-like products face substantial competition from OTC Narcan and RiVive nasal sprays.
• Institutional markets remain the most credible commercial opportunity for an injectable auto-injector.
• Higher-concentration, heat-stable, low-volume, and prefilled presentations offer the clearest formulation-led opportunities.
• Manufacturing barriers center on sterile filling, container compatibility, dose accuracy, device reliability, and human-factors validation.
• Paragraph IV risk depends mainly on the scope of device and method-of-use claims, not on basic naloxone composition.
• A generic conventional injectable may have lower patent risk than a direct auto-injector copy but also less product differentiation.
• Commercial success requires a measurable advantage in cost, storage, usability, procurement, or delivery reliability.

FAQs

Can a new naloxone product use the same EVZIO excipients?

A new product can generally use conventional excipients such as sodium chloride, hydrochloric acid, and water for injection if it satisfies applicable regulatory, quality, and compatibility requirements. Patent risk depends on the full formulation and device claim set, not on excipient identity alone.

Is a preservative-free naloxone auto-injector commercially preferable?

Yes, for a single-use emergency product. Preservative-free design reduces excipient burden and avoids preservative compatibility issues, but it requires strong sterility assurance and container closure control.

Would a higher-dose naloxone auto-injector have a stronger patent position?

Not automatically. A higher-dose or higher-concentration product may support patent claims only if the formulation provides an unexpected stability, delivery, tolerability, or device-performance benefit.

Can naloxone auto-injectors be sold over the counter?

An OTC auto-injector would require FDA authorization for the specific product and user population. FDA's OTC approvals for naloxone nasal sprays do not automatically authorize an OTC injectable auto-injector.

What is the lowest-risk follow-on product to EVZIO?

A conventional prefilled syringe or vial-based injectable with a distinct device configuration is generally less exposed to auto-injector-specific patent claims. It also faces greater price competition and less differentiation from existing generic naloxone injections.

References

1. U.S. Food and Drug Administration. (2016). EVZIO (naloxone hydrochloride injection) prescribing information. Kaleo, Inc.

2. U.S. Food and Drug Administration. (2023). FDA approves first over-the-counter naloxone nasal spray. FDA.

3. U.S. Food and Drug Administration. (2023). FDA approves second over-the-counter naloxone nasal spray. FDA.